| Total: $459.3 | ||||
Company |
Type Of |
Number |
Amount |
Investors; Placement |
Advancis |
Term loan |
N/A |
$8 |
Merrill Lynch Capital provided the three-year, $8M loan, along with a $4M revolving loan facility (7/6) |
Alfacell |
Private placement of stock and warrants |
6.457S and 6.457SW |
$11.3 |
ProMed Management Inc. and other investors purchased the shares at $1.75 each; the five-year warrants are exercisable at $2.88 per share; C.E. Unterberg, Towbin was placement agent (7/20) |
BioSante |
Private placement of stock and warrants |
3.813S and 1.334W |
$7.63 |
Shares were sold at $2 each; warrants are exercisable at $2.75 per share; investors included Perceptive Life Sciences, Quogue Capital, Hunt BioVentures LP, Mallette Capital Management Inc., Valesco Capital Management and Paramount BioCapital affiliates; Rodman & Renshaw LLC was placement agent (7/10) |
DeCode |
Private placement of stock |
6S |
$30 |
Shares are being sold from a shelf registration at $5 each; Lehman Brothers Inc. was lead placement agent; Thomas Weisel Partners LLC was co-agent (7/14) |
GTC |
Private placement of stock and warrants |
12S and 7.8W |
$17.5 |
William Harris Investors Inc. and other investors purchased the registered shares at $1.38 each; the warrants, which cost $0.125 each, are exercisable for 10 years at $1.4145 per share; C.E. Unterberg, Towbin was lead placement agent; Oppenheimer & Co. and Rodman & Renshaw LLC were co-agents (7/18) |
HemoBioTech |
Warrants exercise |
5.156S |
$5.47 |
Holders of about 5.156M Class A warrants converted them into stock at $1.06 per share (7/17) |
Intercell AG |
Private placement and public offering of stock |
4.737S |
€58.5 |
Shares were sold at €12.36 each in the deal; the €58.5 total does not include proceeds from a similar number of shares sold in the deal by existing shareholders; Merrill Lynch International was lead manager for the deal; Erste Bank and Sal. Oppen-heim Jr. & Cie. were co-managers (7/4) |
Kosan |
Equity financing commitment |
N/A |
N/A |
Kingsbridge Capital Ltd. committed to purchase up to $50M in Kosan stock over three years, at a discount of 6% to 10%; Kosan will determine the timing and amount of any sales (7/19) |
Lorus |
Private |
5S |
C$1.8 ($1.6) |
Technifund Inc. agreed to buy the stock at C$0.36 per share (7/25) |
Lorus Therapeutics Inc. (Canada; TSE:LOR) |
Private placement of stock |
28.8S |
C$10.4 ($9.2) |
HighTech Beteiligungen GmbH & Co. KG is buying the shares at C$0.36 per share (7/14) |
Marshall Edwards Inc. (MSHL) |
Private placement of stock and warrants |
6.33S and 2.215W |
$18 |
Units consisting of stock and warrants were sold at $2.90 each; the four- ear warrants are exercisable at $4.35 per share; Janney Montgomery Scott LLC was placement agent; separately, Cornell Capital Partners LP committed to purchase up to $15M in Marshall Edwards stock over two years, at the company's discretion (7/12) |
MicroIslet |
Private placement of stock and warrants |
2.55S and 1.4W |
$3.9 |
The shares were sold at $1.50 and $1.67 each; the five-year warrants are exercisable at $1.65 and $1.67 per share; the higher prices were paid by company insiders participating in the deal (7/27) |
Micromet |
Private placement of stock and warrants |
2.222S and 0.556W |
$8 |
Funds managed by NGN Capital LLC are buying the stock at $3.60 per share; the warrants are exercisable at $5.00 per share; Cowen and Co. was placement agent (7/24) |
MultiCell |
Private placement of convertible stock and warrants |
N/A and 10.5W |
$1.7 |
Investors purchased 17,000 shares of convertible stock; they initially are convertible into common stock at $0.32 per share; the warrants are exercisable at $0.35 per share; investors were Monarch Pointe Fund Ltd., Mercator Momentum Fund III LP, Asset Managers International Ltd. and Pentagon Special Purpose Fund Ltd. (7/20) |
New River |
Private placement of convertible notes |
N/A |
$135 |
The 3.5% notes due in 2013 initally are convertible into stock at about $34.39 per share; totals include the purchase of $10M in notes per the investors' overallotment option (7/19) |
Oragenics |
Warrants exercise |
1.05S |
$0.6 |
Existing investors exercised warrants to purchase 1.05M shares (7/5) |
Oscient |
Royalty, equity and debt sales |
11.1S and N/A |
$70 |
Paul Capital Partners' Paul Royalty Fund II LP is paying $40M for a royalty interest in Antara and Factive, $20M for debt due in 2010, and $10M for stock at $0.90 per share; Paul Royalty also gets warrants to buy 2.3M shares $0.868 per share (7/26) |
ProStrakan |
Private placement of stock |
12.435S |
£11.3 ($22.1) |
Investors purchased the shares at £0.91 each; Morgan Stanley Securities Ltd. and Piper Jaffray Ltd. managed the deal (7/13) |
Protalex Inc. |
Private placement of stock and warrants |
6.1S and 1.5W |
$15.2 |
Investing in the financing were LBI Group Inc., vSpring Capital, CIDC Inc., Emerging Technology Partners and others; Griffin Securities Inc. was lead placement agent (7/10) |
Transgene |
Warrants exercise |
1.778S |
€14.3 ($18) |
Investors in a July 2005 financing exercised warrants issued in that deal to purchase about 1.778M shares at €8.05 per share (7/24) |
Viragen |
Private placement of stock and preferred stock |
3.6S and N/A |
$1.8 |
Investors purchased units consisting of 3.6M common shares and 18,000 shares of Series C 24% cumulative preferred stock; Dawson James Securities Inc. was placement agent (7/28) |
Notes: | ||||
This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
N/A = Not applicable; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vienna Stock Exchange. | ||||
To read more on related topics, click on one of the words below.